An Exploratory Study of Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Latest Information Update: 22 Jun 2022
At a glance
- Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
Most Recent Events
- 01 Jun 2022 Results published in the Nature
- 18 Jan 2022 Status changed from completed to discontinued.
- 18 Jan 2022 The primary endpoint was changed from To evaluate safety and tolerability of multiple 3BNC117 and 10-1074 doses to Participants With Grade 3 or Higher Adverse Events, according to ClinicalTrials.gov record.